Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 3/20 | 0.55 |
| ▸ | BLM | P54132 | 3/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidolate SCHEMBL28832658 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP3A4CYP1A2HTTTP53 | |
| Piperidolate SCHEMBL437741 | 0.99 | CYP3A4 (1.00) | CYP2D6CYP3A4CYP1A2HTTTP53 | |
| Piperidolate SCHEMBL2734595 | 0.99 | CYP2D6 (0.98) | CYP2D6CYP3A4CYP1A2HTTTP53 | |
| Piperidolate SCHEMBL1649482 | 0.98 | CYP2D6 (0.95) | CYP2D6CYP3A4CYP1A2HTTTP53 | |
| SCHEMBL14128808 | 0.92 | CYP2D6 (0.86) | CYP2D6CYP3A4CYP1A2HTTTP53 | |
| SCHEMBL14125434 | 0.92 | CYP2D6 (0.86) | CYP2D6CYP3A4CYP1A2HTTTP53 | |
| SCHEMBL24671287 | 0.86 | CYP3A4 (0.76) | CYP2D6CYP3A4CYP1A2HTTTP53 | |
| SCHEMBL7588607 | 0.84 | CYP2D6 (0.73) | CYP2D6CYP3A4CYP1A2HTTTP53 | |
| SCHEMBL24671171 | 0.83 | CYP2D6 (1.00) | CYP2D6CYP3A4CYP1A2HTTTP53 | |
| SCHEMBL10517675 | 0.80 | CYP2D6 (0.70) | CYP2D6CYP3A4CYP1A2HTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| WO-2025038382-A1 | PHARMACEUTICAL ADHESIVE COMPOSITIONS | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| US-11065205-B2 | Immediate/delayed drug delivery | DRUG DELIVERY INTERNATIONAL LIMITED (GB) | 2021-07-20 | — | — | US | claimed |
| US-20210154208-A1 | Method to Identify Agents That Can Overcome Inhibition Caused By Drug-protein Binding of the Human Plasma Protein, Alpha-1-acid Glycoprotein | THE JOHNS HOPKINS UNIVERSITY | 2021-05-27 | — | — | US | claimed |
| US-10987316-B2 | Compositions and methods for transdermal delivery of tertiary amine drugs | NOVEN PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | claimed |
| EP-3773556-A1 | COMPOSITIONS AND METHODS FOR INCREASING REMYELINATION | Frequency Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-10689370-B2 | Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator | AUSPEX PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | claimed |
| US-20190336490-A1 | COMPOSITIONS AND METHODS FOR INCREASING REMYELINATION | Frequency Therapeutics, Inc. | 2019-11-07 | — | — | US | claimed |
| EP-2026807-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHOD AND COMPOSITIONS | Universita' Degli Studi di Torino (IT) | 2009-02-25 | — | — | EP | claimed |
| WO-2009018169-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20090028873-A1 | SUBSTITUTED CYCLOHEXANOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007135574-A1 | USE OF PARASYMPATHOLYTIC SUBSTANCES TO ENHANCE AND ACCELERATE STEM CELL DIFFERENTIATION, RELATED METHOD AND COMPOSITIONS | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2007-11-29 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689370-B2 | Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator | CFTR, CLCN2, TMEM120A | CYP2D6 4330/4885CYP3A4 4062/4885CYP1A2 4452/4885 |
| US-20090028873-A1 | SUBSTITUTED CYCLOHEXANOLS | OPRM1, OPRD1, OPRK1 | CYP2D6 57/4885CYP3A4 162/4885CYP1A2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.